Search

Your search keyword '"Conte, Miriam"' showing total 18 results
Start Over Author "Conte, Miriam" Publisher mdpi ag
18 results on '"Conte, Miriam"'

1. FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature

Author

Guglielmo, Priscilla, primary, Alongi, Pierpaolo, additional, Baratto, Lucia, additional, Conte, Miriam, additional, Abenavoli, Elisabetta Maria, additional, Buschiazzo, Ambra, additional, Celesti, Greta, additional, Dondi, Francesco, additional, Filice, Rossella, additional, Gorica, Joana, additional, Jonghi-Lavarini, Lorenzo, additional, Laudicella, Riccardo, additional, Librando, Maria, additional, Linguanti, Flavia, additional, Mattana, Francesco, additional, Miceli, Alberto, additional, Olivari, Laura, additional, Piscopo, Leandra, additional, Santo, Giulia, additional, Volpe, Fabio, additional, and Evangelista, Laura, additional

Published
2024
Full Text
View/download PDF

3. Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature

Author

Guglielmo, Priscilla, primary, Alongi, Pierpaolo, additional, Baratto, Lucia, additional, Abenavoli, Elisabetta, additional, Buschiazzo, Ambra, additional, Celesti, Greta, additional, Conte, Miriam, additional, Filice, Rossella, additional, Gorica, Joana, additional, Jonghi-Lavarini, Lorenzo, additional, Lanzafame, Helena, additional, Laudicella, Riccardo, additional, Librando, Maria, additional, Linguanti, Flavia, additional, Mattana, Francesco, additional, Miceli, Alberto, additional, Olivari, Laura, additional, Piscopo, Leandra, additional, Romagnolo, Cinzia, additional, Santo, Giulia, additional, Vento, Antonio, additional, Volpe, Fabio, additional, and Evangelista, Laura, additional

Published
2023
Full Text
View/download PDF

7. Abscopal Effect on Bone Metastases from Solid Tumors: A Systematic Review and Retrospective Analysis of Challenge within a Challenge

Author

Tomaciello, Miriam, primary, Conte, Miriam, additional, Montinaro, Francesca Romana, additional, Sabatini, Arianna, additional, Cunicella, Giorgia, additional, Di Giammarco, Federico, additional, Tini, Paolo, additional, Gravina, Giovanni Luca, additional, Cortesi, Enrico, additional, Minniti, Giuseppe, additional, De Vincentis, Giuseppe, additional, Frantellizzi, Viviana, additional, and Marampon, Francesco, additional

Published
2023
Full Text
View/download PDF

18. Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?

Author

Dondi F, Miceli A, Rovera G, Feudo V, Battisti C, Rondini M, Marongiu A, Mura A, Camedda R, De Feo MS, Conte M, Gorica J, Ferrari C, Nappi AG, and Santo G

Abstract

Introduction: The term theragnostic refers to the combination of a predictive imaging biomarker with a therapeutic agent. The promising application of prostate-specific membrane antigen (PSMA)-based radiopharmaceuticals in the imaging and treatment of prostate cancer (PCa) patients opens the way to investigate a possible role of PSMA-based radiopharmaceuticals in cancers beyond the prostate. Therefore, the aim of this review was to evaluate the role of 177 Lu-PSMA radioligand therapy (RLT) in malignancies other than prostate cancer by evaluating preclinical, clinical studies, and ongoing clinical trials., Methods: An extensive literature search was performed in three different databases using different combinations of the following terms: "Lu-PSMA", " 177 Lu-PSMA", "preclinical", "mouse", "salivary gland cancer", "breast cancer", "glioblastoma", "solid tumour", "renal cell carcinoma", "HCC", "thyroid", "salivary", "radioligand therapy", and "lutetium-177". The search had no beginning date limit and was updated to April 2024. Only articles written in English were included in this review., Results: A total of four preclinical studies were selected (breast cancer model n = 3/4). PSMA-RLT significantly reduced cell viability and had anti-angiogenic effects, especially under hypoxic conditions, which increase PSMA binding and uptake. Considering the clinical studies (n = 8), the complexity of evaluating PSMA-RLT in cancers other than prostate cancer was clearly revealed, since in most of the presented cases a sufficient tumour radiation dose was not achieved. However, encouraging results can be found in some types of diseases, such as thyroid cancer. Some clinical trials are still ongoing, and results from prospective larger cohorts of patients are awaited., Conclusions: The need for larger patient cohorts and more RLT cycles administered underscores the need for further comprehensive studies. Given the very preliminary results of both preclinical and clinical studies, ongoing clinical trials in the near future may provide stronger evidence of both the safety and therapeutic efficacy of PSMA-RLT in malignancies other than prostate cancer.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results